Vancomycin-resistant enterococci (VRE) are major nosocomial pathogens that have been observed worldwide (1,2). VRE were identified in Canada in 1993 (3), but rates of colonization and infection have remained relatively low for years (4,5). VRE bloodstream infections (BSIs) are of particular concern because they are associated with increased illness, length of hospital stay, healthcare costs, and death (6–8). Furthermore, increased rates of VRE BSI have been reported (8).

Since 1999, the Canadian Nosocomial Infection Surveillance Program (CNISP) has conducted surveillance of VRE BSIs, which includes collection of patient epidemiologic data and laboratory analysis of blood isolates, including multilocus sequence typing (MLST) and antimicrobial drug susceptibility testing (5,9). The MLST scheme for Enterococcus faecium relies on the sequences of 7 essential housekeeping genes (10). However, in recent years, MLST nontypeable strains of E. faecium have emerged that do not harbor the pstS gene (11). These pstS-null sequence types (e.g., sequence type [ST] 1421 and ST1424) are believed to have occurred through multiple inversion events and have been reported to be rapidly spreading in Australia, Denmark, and the United Kingdom (11–13). We report emergence and molecular characterization of a pstS-null sequence type (ST1478) that is rapidly disseminating across acute care hospitals in Canada.

The Study

CNISP is administered by the Public Health Agency of Canada and has conducted prospective surveillance for VRE infection and colonization since 1999 (5,9). CNISP is a partnership between the Centre for Communicable Disease and Infection Control and the National Microbiology Laboratory at the Public Health Agency of Canada and sentinel hospitals that participate as members of the Canadian Hospital Epidemiology Committee, a subcommittee of the Association of Medical Microbiology and Infectious Diseases Canada. Hospitalized patients with enterococcal bacteremia characterized as having vancomycin MICs ≥8 mg/L were eligible (9). A patient was included more than once if a positive VRE blood isolate was identified >14 days after completion of therapy for a previous infection and believed to be unrelated to previous infection in accordance with best clinical judgement (9). Epidemiologic data were collected and VRE BSI isolates were forwarded to the National Microbiology Laboratory for further characterization (9).
All isolates that failed to give a sequence type by conventional MLST (10) were subjected to whole-genome sequencing on the MiSeq Platform (Illumina, https://www.illumina.com). Assembled reads (contigs) were analyzed by using an in-house MLST tool based on 1 from the Center for Genomic Epidemiology website (https://cge.cbs.dtu.dk/services).

During 2013–2018, a total of 797 VRE BSI cases were reported among 62 participating acute care hospitals across 10 provinces for which 608 VRE BSI isolates were submitted. During this surveillance period, the rate of VRE BSI significantly increased from 0.16 cases/10,000 patient-days to 0.34 cases/10,000 patient-days (p<0.001) (Figure). These rates are much higher than those reported during 1999–2009 (0.005 cases/1,000 admissions during 1999 to 0.068 cases/1,000 admissions during 2009) (5). Of the 608 VRE BSI collected, different MLST types were identified, which included 4 of the newly reported pstS-null sequence types ST1478 (n = 115), ST1421 (n = 7), ST1424 (n = 2), and ST1612 (n = 1). The increase of ST1478 isolates from 2.7% in 2013 to 38.7% in 2018 coincides with the increase in VRE BSI rates (Figure). After emergence of ST1478, STs that once dominated (ST18, ST117, and ST412) dramatically decreased. This shift in clonal types is similar to what has been reported in other countries after identification of these pstS-null mutants (12).

As of 2018, ST1478 has been identified in 19 of 62 CNISP participating hospitals in 6 provinces. Of the 19 hospitals, 12 were from western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba), 6 from central Canada (Ontario and Quebec), and 1 from eastern Canada (Newfoundland and Labrador, Prince Edward Island, New Brunswick, and Nova Scotia). Regionally, ST1478 represented 23.7% (65/274) of isolates tested from western Canada, 14.8% (49/332) of isolates tested from central Canada, and 50% (1/2) of isolates tested from eastern Canada during 2013–2018. Furthermore, among the VRE BSI identified in western Canada, a significantly higher proportion were ST1478 isolates from 2.7% in 2013 to 38.7% in 2018 coincides with the increase in VRE BSI rates (Figure). After emergence of ST1478, STs that once dominated (ST18, ST117, and ST412) dramatically decreased. This shift in clonal types is similar to what has been reported in other countries after identification of these pstS-null mutants (12).

As of 2018, ST1478 has been identified in 19 of 62 CNISP participating hospitals in 6 provinces. Of the 19 hospitals, 12 were from western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba), 6 from central Canada (Ontario and Quebec), and 1 from eastern Canada (Newfoundland and Labrador, Prince Edward Island, New Brunswick, and Nova Scotia). Regionally, ST1478 represented 23.7% (65/274) of isolates tested from western Canada, 14.8% (49/332) of isolates tested from central Canada, and 50% (1/2) of isolates tested from eastern Canada during 2013–2018. Furthermore, among the VRE BSI identified in western Canada, a significantly higher proportion were

### Table 1. Antimicrobial drug resistance results for ST1478 versus non-ST1478 isolates of vancomycin-resistant enterococci, Canada, 2013–2018*

| Antimicrobial drug          | % ST1478, n = 115 | % Non-ST1478, n = 493 | p value |
|-----------------------------|-------------------|------------------------|---------|
| Ampicillin                  | 100.0             | 100.0                  | 1       |
| Chloramphenicol             | 10.4              | 1                      | 0.001   |
| Ciprofloxacin               | 100.0             | 100.0                  | 1       |
| Daptomycin                  | 13.0              | 3.9                    | 0.014   |
| Erythromycin                | 100.0             | 92.1                   | 0.0001  |
| HL gentamicin               | 80.0              | 13.6                   | 1       |
| Levofloxacin                | 100.0             | 99.6                   | 1       |
| Linezolid                   | 1.7               | 0.4                    | 0.1669  |
| Nitrofurantoin              | 16.5              | 35.9                   | 0.002   |
| Penicillin                  | 100.0             | 100.0                  | 1       |
| Quinupristin/dalfopristin   | 0.9               | 8.5                    | 0.0032  |
| Rifampin                    | 95.7              | 90.1                   | 0.7104  |
| HL streptomycin             | 15.7              | 39.8                   | 0.0002  |
| Tetracycline                | 91.3              | 46.0                   | 0.0001  |
| Tigecycline                 | 0.9               | 0.4                    | 0.4776  |
| Vancomycin                  | 100.0             | 97.2                   | 0.8835  |

*HL, high level; ST, sequence type.
ST1478 (56.5%, 65/115) compared with non-ST1478 (42.4%, 209/493; p = 0.006).

The predominant van gene among ST1478 isolates was vanA (99.1%, n = 114); only 1 isolate harbored a vanB gene (0.9%). We determined resistance to antimicrobial drugs by using broth microdilution and GPALLIF Sensititer panels (Trek Diagnostics, http://www.trekds.com). We interpreted MICs by using breakpoints described by the Clinical and Laboratory Standards Institute (14). Antimicrobial drug susceptibility tests showed that ST1478 isolates have increased resistance to chloramphenicol (10.4%), daptomycin (13.0%), HL-gentamicin (80.0%), and tetracycline (91.3%) compared with non-ST1478 isolates (Table 1). We verified daptomycin nonsusceptibility by using Etest (bioMérieux, https://www.biomerieux.com). Clinically, increased daptomycin nonsusceptibility among the ST1478 isolates is of particular concern because daptomycin is 1 of the few remaining treatment options for VRE and resistance to it is an increasing clinical problem (15). CNISP surveillance data show a nonsignificant increase in the use of daptomycin to treat patients with VRE bloodstream infections. During 2015, a total of 53.7% of patients with a VRE BSI were given daptomycin, and during 2018, this proportion increased to 61.1% (p = 0.5).

During 2013–2018, we identified 115 ST1478 VRE BSI isolates among 110 patients. The median age of ST1478 patients was 58 years (interquartile range 52–69 years), and most (63.1%, 69/111) were male. The most commonly identified risk factors at the time of positive culture included use of a central venous catheter (69.5%, 57/82), solid organ transplant recipient (24.7%, 24/97), receiving hemodialysis (21.4%, 15/70), and receiving chemotherapy (15.7%, 11/70). A total of 31% (28/92) of ST1478 patients were already in an intensive care unit at the time of positive culture, and an additional 11 (12.1%) were admitted within 30 days of positive blood culture. The all cause 30-day mortality rate was 32.4%. Bacteremia patients with ST1478 VRE were similar with respect to age, sex, intensive care unit admission, and mortality rate compared with patients who had non-ST1478 VRE. Patients with ST1478 VRE were more likely to have undergone solid organ transplantation (24.7%) than patients with non-ST1478 VRE (12.9%; p = 0.005) (Table 2). However a VRE outbreak was reported by 1 center in their multiorgan transplant unit, which might explain this finding.

### Conclusions

The emergence of the psl5-null mutant ST1478 identified in acute care hospitals in Canada coincides with a major increase in VRE BSI rates. This increase might be attributed to an increased virulence/fitness of this strain type or changes in VRE infection prevention and control practices.

Clinically, the increased proportion of daptomycin nonsusceptibility among this emerging strain type is of concern. Future work, including whole-genome sequencing, and collection of enhanced epidemiologic and infection prevention and control practices data are being undertaken to provide a better understanding of the transmission, clonal relatedness, and evolution of this strain type within and between hospitals across Canada. Clinicians should be aware of these drug-resistant bacteria.

### Acknowledgments

We thank the physicians, epidemiologists, infection control practitioners, and laboratory staff at each participating hospital for their contributions to the study and Sean Ahmed and Ken Fakharuddin for providing expert technical assistance.

### About the Author

Ms. McCracken is a microbiologist at the National Microbiology Laboratory in Winnipeg, Manitoba, Canada. Her primary research interests are vancomycin-resistant enterococci and methicillin-resistant *Staphylococcus aureus*.
References

1. Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet. 1988;1:57–8. https://doi.org/10.1016/S0140-6736(88)91037-9
2. Bonten MJ, Willems R, Weinstein RA. Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis. 2001;1:314–25. https://doi.org/10.1016/S1473-3099(01)00145-1
3. Kibsey PC, Willey B, Low DE, Cain D, Boychuk LR, Huele M. Vancomycin multiresistant Enterococcus faecium: first Canadian isolate. Presented at: 61st Conjoint Meeting on Infectious Diseases. Canadian Association for Clinical Microbiology and Infectious Diseases; Vancouver, British Columbia, Canada; November 8–10, 1993. Abstract K5.
4. Ofner-Agostini M, Johnston BL, Simor AE, Embil J, Matlow A, Mulvey M, et al.; Canadian Nosocomial Infection Surveillance Program. Vancomycin-resistant enterococci in Canada: results from the Canadian nosocomial infection surveillance program, 1999–2005. Infect Control Hosp Epidemiol. 2008;29:271–4. https://doi.org/10.1086/528812
5. McCracken M, Wong A, Mitchell R, Gravel D, Conly J, Embil J, et al.; Canadian Nosocomial Infection Surveillance Program. Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999–2009. J Antimicrob Chemother. 2013;68:1505–9. https://doi.org/10.1093/jac/dkt054
6. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007;58:163–70. https://doi.org/10.1016/j.diagmicrobio.2006.12.022
7. Lu C-L, Chuang Y-C, Chang H-C, Chen YC, Wang JT, Chang SC. Microbiological and clinical characteristics of vancomycin-resistant Enterococcus faecium bacteraemia in Taiwan: implication of sequence type for prognosis. J Antimicrob Chemother. 2012;67:2243–9. https://doi.org/10.1093/jac/dks181
8. Prematunge C, MacDougall C, Johnstone J, Adomako K, Lam F, Robertson J, et al. VRE and VSE bacteremia outcomes in the era of effective VRE therapy: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2016;37:26–35. https://doi.org/10.1017/ice.2015.228
9. Public Health Agency of Canada. Surveillance protocol for vancomycin-resistant Enterococcus bloodstream infections in CNISP hospitals, 2019 [cited 2020 Apr 30]. https://ipac-canada.org/cnisp-publications.php
10. Homan WL, Tribe D, Poznanski S, Li M, Hogg G, Spalburg E, et al. Multilocus sequence typing scheme for Enterococcus faecium. J Clin Microbiol. 2002;40:1963–71. https://doi.org/10.1128/JCM.40.6.1963-1971.2002
11. Carter GP, Buljtjen AH, Ballard SA, Baines SL, Tomita T, Strachan J, et al. Emergence of endemic MLST non-typeable vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother. 2016;71:3367–71. https://doi.org/10.1093/jac/dkw314
12. Hammerum AM, Justesen US, Pinholdt M, Roer L, Kaya H, Worning P, et al. Surveillance of vancomycin-resistant enterococci reveals shift in dominating clones and national spread of a vancomycin-variable vanA Enterococcus faecium ST1421-CT1134 clone, Denmark, 2015 to March 2019. Euro Surveill. 2019;24:1–5. https://doi.org/10.2807/1560-7917.ES.2019.24.34.1900503
13. Lemonidis K, Salih TS, Dancer SJ, Hunter IS, Tucker NP. Emergence of an Australian-like pstS-null vancomycin resistant Enterococcus faecium clone in Scotland. PLoS One. 2019;14:e0218185. https://doi.org/10.1371/journal.pone.0218185
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 20th Informational Supplement M100–S20. Wayne (PA): The Institute; 2018.
15. Kinnear CL, Patel TS, Young CL, Marshall V, Newton DW, Read AF, et al. Impact of an antimicrobial stewardship intervention on within- and between-patient daptomycin resistance evolution in vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 2019;63:e01800-18. https://doi.org/10.1128/AAC.01800-18

Address for correspondence: Melissa McCracken, Public Health Agency of Canada, 1015 Arlington St, Winnipeg, MB R3C 4W1, Canada; email: melissa.mccracken@canada.ca